A Systematic Overview of Chemotherapy Effects in Hodgkin's Disease

References

• Cancer incidence in Sweden 1997. Stockholm: National Board of Health and Welfare, Centre for Epidemiology, The Cancer Registry, 1999.
   Google Scholar
• Abrahamsen AF, Hannisdal E, Nome O, et al. Clinical stage I and II Hodgkin's disease: Long-term results of therapy without laparotomy. Ann Oncol 1996; 7: 147-50. (P1/313)
   Google Scholar
• Van Spronsen DJ, Dijkema IM, Vrits LW, et al. Improved survival of Hodgkin's patients in South-East Netherlands since 1972. Eur J Cancer 1997; 33: 436-41. (L1)
   Google Scholar
• Lister AT, Crowther D. Staging for Hodgkin's disease. Semin Oncol 1990; 17: 696–703.
   PubMed Web of Science ®Google Scholar
• Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European task force on lymphoma project on lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1999; 17: 776-83. (01)
   PubMedGoogle Scholar
• Anderson H, Deakin D, Wagstaff J, et al. A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: A re-port from the Manchester lymphoma group. Br J Cancer 1984; 49: 695-702. (C2/114)
   Google Scholar
• Andrieu JM, Dana M, Desprez-Curely JP, et al. MOPP chemotherapy plus irradiation for Hodgkin's disease, stages IA to HIB. Long-term results of the prospective trial H72 (1972-1976, 334 patients). Hematol Oncol 1985; 3: 219–31. (P2/334)
   Google Scholar
• Anselmo A, Bove M, Cartoni C, et al. Combined modality (ABVD plus radiotherapy) versus radiotherapy in the man-agement of early stage (HA) Hodgkin's disease with me-diastinal involvement. Haematol 1992; 77: 177-9. (C3/73)
   Google Scholar
• Bonfante V, Santoro A, Viviani S, et al. Early stage Hodgkin's disease: Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP. Eur J Cancer 1993; 29A: 24-9. (P2/201)
   Google Scholar
• Carde P, Burgers J, Henry Amar M, et al. Clinical stages I and II Hodgkin's disease: A specifically tailored therapy according to prognostic factors. J Clin Oncol 1988; 6: 239-52. (C1/494)
   Google Scholar
• Cosset M, Henry Amar M, Meerwaldt J, et al. The EORTC trials for limited Hodgkin's disease. Eur J Cancer 1992; 28A: 1847-50. (C1/1641)
   Google Scholar
• Nordentoft A, Nissen N, Bjorn Jensen K. Experiences from the national Danish study group (LYGRA) with respect to diagnosis, classification and treatment of Hodgkin's disease. Acta Radiol Oncol 1984; 23: 163-7. (C1/310)
   Google Scholar
• Rosenberg S, Kaplan H. The evolution and summary results of the Stanford randomised clinical trials of the management of Hodgkin's disease 1962-1984. Int J Radiat Oncol Biol Phys 1985; 11: 5-22. (C2/835)
   Google Scholar
• Straus D, Yahalom J, Gaynor J, et al. Four cycles of chemotherapy and regional radiation therapy for clinical early-stage and intermediate stage Hodgkin's disease. Cancer 1992; 69: 1052-60. (C2/120)
   Google Scholar
• Tubiana M, Henry-Amar M, Carde P, et al. Toward com-prehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 1989; 73: 47–56. (C1/1579)
   Google Scholar
• Shore T, Nelson N, Weinerman B. A meta-analysis of stages I and II Hodgkin's disease. Cancer 1990; 65: 1155-60. (M2/2999)
   Google Scholar
• Specht L, Gray RG, Clarke MJ, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early stage Hodgkin's disease: A meta-anal-ysis of 23 randomised trials involving 3 888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998; 16: 830-43. (M1/3888)
   Google Scholar
• Horning SJ, Hoppe RT, Mason J, et al. Stanford-Kaiser permanent G1 study for clinical stage I to HA Hodgkin's disease: Subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 1997; 15: 1736-44. (C2/78)
   Google Scholar
• Tesch H, Sieber M, Rfiffer JU, et al. 2 cycles ABVD plus radiotherapy is more effective than radiotherapy alone in early stage HD - Results of the HD7 trial of the GHSG. VII Int Conf Malign Lymph, Lugano, 1999; 249 Abstr. (C3/640)
   Google Scholar
• Gospadarowicz M, Sutcliffe S, Bergsagel D, et al. Radiation therapy in clinical stage I and II Hodgkin's disease. Eur J Cancer 1992; 28A: 1841-6. (R1/731)
   Google Scholar
• Haybittle J, Easterling M, Benett M, et al. Review of British National Lymphoma Investigation studies of Hodgkin's dis-ease and development of prognostic index. Lancet 1985; 1: 967-72. (C1/743)
   Google Scholar
• Brusamolino E, Lazzarino M, Orlandi E, et al. Early stage Hodgkin's disease: Long term results with radiotherapy alone or combined radiotherapy and chemotherapy. Ann Oncol (Suppl) 1994; 5: 101-6. (P1/164)
   Google Scholar
• Ziltoun R, Audebert A, Hoerni B, et al. Extended versus involved field irradiation combined with MOPP chemother-apy in early clinical stages of Hodgkin's disease. J Clin Oncol 1985; 3: 207-14. (C2/335)
   Google Scholar
• Hartsen W, Sarin P, Recine D, et al. Long-term results of curative irradiation in pathologically staged IA and HA Hodgkin's disease. Radiol 1993; 186: 565-8. (R1/176)
   Google Scholar
• Mauch P, Tarbell N, Weinstein H, et al. Stage IA and HA supradiaphragmatic Hodgkin's disease: Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 1988; 6: 1576-83. (R1/315)
   Google Scholar
• Wirth A, Chao M, Cony J, et al. Mantle irradiation alone for clinical stage I-II Hodgkin's disease: Long-term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol 1999; 17: 230-40. (R1/261)
   Google Scholar
• Glimelius B, Kälkner M, Enblad G, et al. Treatment of early and intermediate stages of supradiaphragmatic Hodgkin's disease: The Swedish National Care Program experience. Ann Oncol 1994; 5: 809-16. (R1/210)
   Google Scholar
• Hughes-Davies L, Tarbell NJ, Coleman CN, et al. Stage IA-IIB Hodgkin's disease: Management and outcome of extensive thoracic involvement. Int J Radiat Oncol Biol Phys 1997; 39: 361–9. (R1/172)
   PubMed Web of Science ®Google Scholar
• Leopold K, Canellos G, Rosenthal D, et al. Stage IA-IIB Hodgkin's disease: Staging and treatment of patients with large mediastinal adenopathy. J Clin Oncol 1989; 7: 1059-65. (R2/92)
   Google Scholar
• Tarbell N, Thomson L, Mauch P. Thoracic irradiation in Hodgkin's disease: Disease control and long-term complica-tions. Int J Radiat Oncol Biol Phys 1990; 18: 275-81. (R1/590)
   Google Scholar
• Zinzani P, Mazza P, Gherlinzoni F, et al. Massive mediasti-nal involvement in stage I-II Hodgkin's disease: Response to combined modality treatment. Leuk Lymphoma 1992; 8: 81-5. (P2/37)
   Google Scholar
• Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: A report from the international database on Hodgkin's disease. Ann Oncol (Suppl) 1992; 3 (4): 117–28. (R1/12411)
   Google Scholar
• Swerdlow AJ, Barber JA, Vaughan Hudson G, et al. Risk of second malignancy after Hodgkin's disease in a large cohort of patients in Britain. Leuk Lymphoma 1998;29 (Suppl 1): 012 Abstr. (R3/5519)
   Google Scholar
• Hoppe RT. Hodgkin's disease. Complications of therapy and excess mortality. Ann Oncol (Suppl) 1997; 8: 115-8. (L1)
   Google Scholar
• Biti GP, Cimino G, Cartoni C, et al. Extended-field radio-therapy is superior to MOPP chemotherapy for the treat-ment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 1992; 10: 378-82. (C3/89)
   Google Scholar
• Longo DL, Glatstein E, Duffey PL, et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. J Clin Oncol 1991; 9: 906-17. (C3/105)
   Google Scholar
• Riiffer U, Sieber M, Pfistner B, et al. Involved field radiation is as effective as extended field radiation following chemotherapy for intermediate stage Hodgkin's disease ex-pecting a reduction of long term side-effects: Interim analysis of the HD8 trial (GHSG). VII Int Conf Malign Lymph, Lugano 1999; 250 Abstr. (C3/742)
   Google Scholar
• Brada M, Ashley S, Nichols J, et al. Stage III Hodgkin's disease-long term results following chemotherapy, radiother-apy and combined modality therapy. Radiother Oncol 1989; 14: 185-98. (R2/215)
   Google Scholar
• Levitt S, Lee C, Aeppli D, et al. The role of radiation therapy in Hodgkin's disease: Experience and controversy. The 54th annual Janeway lecture 1989. Cancer 1992; 70: 693–703. (P2/179)
   Google Scholar
• Mauch P, Goffman T, Rosenthal D, et al. Stage III Hodgkin's disease: Improved survival with combined modal-ity therapy as compared with radiation therapy alone. J Clin Oncol 1985; 3: H66-73. (R2/120)
   Google Scholar
• Pavlovsky S, Santarelli M, Sackman MF, et al. Randomised trial of chemotherapy versus chemotherapy plus radiother-apy for stage III-WA & B Hodgkin's disease. Ann Oncol 1992; 3: 533-7. (C3/151)
   Google Scholar
• Prosnitz L, Cooper D, Cox E, et al. Treatment selection for stage MA Hodgkin's disease patients. Int J Radiat Oncol Biol Phys 1985; H: 1431–7. (R2/85)
   Google Scholar
• Oza A, Leahy M, Lim J, et al. The treatment of stage IIIA Hodgkin's disease-total nodal irradiation versus combination chemotherapy: Either or neither. J Clin Oncol 1991; 9: 1514-6. (R2/85)
   Google Scholar
• Hancock B, Vaughan Hudson G, Vaughan Hudson B, et al. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in ad-vanced Hodgkin's disease-long term results. Br J Cancer 1991; 63: 759-82. (C1/290)
   Google Scholar
• Oza A, Ganesan T, Doreen M, et al. Patterns of survival in patients with advanced Hodgkin's disease (HD) treated in a single centre over 20 years. Br J Cancer 1992; 65: 429-37. (R1/164)
   Google Scholar
• Urba W, Longo D. Hodgkin's disease. N Engl J Med 1992; 326: 678-87. (L1)
   PubMedGoogle Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-14. (01)
   PubMedGoogle Scholar
• Frei E, Luce JK, Gamble JF, et al. Combination chemother-apy in advanced Hodgkin's disease. Induction and mainte-nance of remission. Ann Intern Med 1973; 79: 376-82. (C3/178)
   Google Scholar
• Young RC, Canellos GP, Chabner BA, et al. Maintenance chemotherapy for advanced Hodgkin's disease in remission. Lancet 1973; 1: 1339-43. (C3/57)
   Google Scholar
• Björkholm M, Axdorph U, Grimfors G, et al. Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. Ann Oncol 1995; 6: 895–9. (C3/88)
   Google Scholar
• Yelle L, Bergsagel D, Baseo V, et al. Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicen-ter clinical trial. J Clin Oncol 1991; 9: 1983-93. (C2/226)
   Google Scholar
• Diehl V, Loeffler M, Pfreundschuh M, et al. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alter-nating chemotherapy in patients with advanced Hodgkin's disease. Ann Oncol 1995; 6: 901-10. (C1/288)
   Google Scholar
• Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analy-sis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 1998; 16: 818-29. (M1/1740)
   Google Scholar
• Fermé C, Mounier N, Divine M, et al. Extended field irradiation does not improve survival in stage IIIB-IV Hodgkin's disease (HD) in complete remission or good partial response: A randomised study from the GELA. VII Int Conf Malign Lymph, Lugano, 1999; 60 Abstr. (C3/559)
   Google Scholar
• Longo D, Russo A, Duffey P, et al. Treatment of advanced-stage massive mediastinal Hodgkin's disease: The case for combined modality treatment. J Clin Oncol 1991; 9: 227-35. (R3/49)
   Google Scholar
• Brizel D, Winer E, Prosnitz L, et al. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys 1990; 19: 535-42. (R2/154)
   Google Scholar
• Sutcliffe S. Role of radiation therapy in advanced Hodgkin's disease-as yet, an answer? Still a question? Ann Oncol 1992; 3: 499-501. (01)
   Google Scholar
• Enblad G, Glimelius B, Sundström C. Treatment outcome in Hodgkin's disease in patients above the age of 60: A popula-tion based study. Ann Oncol 1991; 2: 291–302. (R1/163)
   Google Scholar
• Glimelius B, Enblad G, Kälkner M, et al. Treatment of Hodgkin's disease: The Swedish National Care Program experience. Leuk Lymphoma 1996; 21: 71-8. (R1/648)
   Google Scholar
• Taylor P, Jackson G, Lucraft H, et al. A novel treatment for Hodgkin's disease in the elderly: P. Come. Leuk Lymphoma 1998; 29 (Suppl 1): 97 Abstr. (P3/18)
   Google Scholar
• DeVita VT Jr, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin's disease with chemotherapy Long-term follow up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92: 587-95. (R1/198)
   Google Scholar
• Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295-306. (R1/198)
   Google Scholar
• Selby P, Patel P, Milan S, et al. Ch1VPP combination chemotherapy for Hodgkin's disease: Long term results. Br J Cancer 1990; 62: 279-85. (R1/284)
   Google Scholar
• Sutcliffe SB, Wrigley PF, Peto J, et al. MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J 1978; 1: 679-83. (R1/133)
   Google Scholar
• Canellos GP, Anderson JR, Propert KJ, et al. Chemother-apy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-84. (C2/361)
   Google Scholar
• Williams ME, Lister TA, Longo DL. Hodgkin's disease and non-Hodgkin's lymphoma. In: McArthur JR, ed. Hematol-ogy 1993. Education Programme American Society of He-matology. St Louis, Missouri: 1993:49–61. (L1)
   Google Scholar
• Goldie JH, Coldman AJ. The genetic origin of drug resis-tance in neoplasms: implications for systemic therapy. Can-cer Res 1984; 44: 3643–53.
   PubMed Web of Science ®Google Scholar
• Longo DL, Duffey PL, DeVita VT, et al. Treatment of advanced-stage Hodgkin's disease: Alternating non cross-re-sistant MOPP/CABS is not superior to MOPP. J Clin Oncol 1991; 9: 1409-20. (C1/125)
   Google Scholar
• Vinciguerra V, Propert KJ, Coleman M, et al. Alternating cycles of combination chemotherapy for patients with recur-rent Hodgkin's disease following radiotherapy. A prospec-tively randomised study by the Cancer and Leukemia Group B. J Clin Oncol 1986; 4: 838-46. (C3/113)
   Google Scholar
• Hancock BW, Vaughan Hudson G, Vaughan Hudson B, et al. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: Re-sults of a British National Lymphoma Investigation Trial. J Clin Oncol 1992; 10: 1228-52. (C1/594)
   Google Scholar
• Somers R, Carde D, Henry-Amar M, et al. A randomised study in stage BIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treat-ment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994; 12: 279-87. (C1/192)
   Google Scholar
• Fermé C, Lepage E, Brice P, et al. Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: Results of a prospective clinical trial with 70 stage IIIB-IV patients. Int J Radiat Oncol Biol Phys 1993; 26: 397–405. (C3/70)
   Google Scholar
• Holte H, Mella O, Witt E, et al. Ch1VPP is as effective as alternating Ch1VPP/ABOD in advanced stage Hodgkin's disease. Acta Oncol 1996; 35 (Suppl 8): 73–80. (C2/100)
   Google Scholar
• Klimo P, Connors J. An update of the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid programme. Semin Hematol (Suppl) 1988; 2 (2): 34–40. (P2/79)
   Google Scholar
• Connors JM, Klimo P, Adams G, et al. Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997; 15: 1638-45. (C1/301)
   Google Scholar
• Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol 1996; 14: 1421-30. (C1/427)
   Google Scholar
• Glick JH, Young ML, Harrington D, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease signifi-cantly improves failure-free and overall survival: The 8-year results of the Intergroup trial. J Clin Oncol 1998; 16: 19-26. (C1/691)
   Google Scholar
• Duggan D, Petroni G, Johnson J, et al. MOPP/ABV versus ABVD for advanced Hodgkin's disease-a preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC). Proc Am Soc Clin Oncol 1997; 16: 43 Abstr. (C3/856)
   Google Scholar
• Radford JA, Crowther D, Rohatiner AZ, et al. Results of a randomised trial comparing MVPP chemotherapy with a hybrid regimen, Ch1VPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol 1995; 13: 2379-85. (C1/423)
   Google Scholar
• Radford JA, Rohatiner AZ, Ryder WD, et al. Fourteen years clinical trial experience with the CHLVPP/EVA hybrid regimen as first line treatment for advanced Hodgkin's dis-ease (HD). VII Int Conf Malign Lymph, Lugano, 1999; 59 Abstr. (C3/419 ± C3/282)
   Google Scholar
• Reuss K, Engert A, Tesch H, et al. Current clinical trials in Hodgkin's disease. Ann Oncol (Suppl) 1996; 7 (4): 109–13. (02)
   Google Scholar
• Diehl V, Sieber M, Ruffer U, et al. BEACOPP: An inten-sified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 1997; 8: 143-8. (P2/30)
   Google Scholar
• Tesch H, Diehl V, Lathan B, et al. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, pro-carbazine, and prednisone scheme and adjuvant radiother-apy: A study of the German Hodgkin's lymphoma study group. Blood 1998; 92: 4560-7. (P2/60)
   Google Scholar
• Diehl V, Franklin J, Hasenclever D, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998; 16: 3810-21. (C1/1200)
   Google Scholar
• Diehl V, Sieber M, Franklin J, et al. Dose escalated BEA-COPP chemotherapy for advanced Hodgkin's diseae: Promising results of the fourth interim analysis of the HD9 trial. VII Int Conf Malign Lymph, Lugano, 1999; 61 Abstr. (C3/1200)
   Google Scholar
• Tesch H, Diehl V, Lathan B, et al. Interim analysis of the HD9 study of the German Hodgkin study group (GHSG) - BEACOPP is more effective than COPP/ ABVD in advanced stage Hodgkin's disease. Leuk Lymphoma 1998; 29 (Suppl 1): 1–5 Abstr. (C3/505)
   Google Scholar
• Gerhartz HH, Schwenke H, Bazarbashi S, et al. Randomised comparison of COPP/ ABVD versus dose-and time-escalated COPP/ABVD with GM-CSF support for advanced Hodgkin's disease. Blood 1997; 90 (Suppl 1) Abstr 1731. (C3/211)
   Google Scholar
• Bonadonna G. Modern treatment of malignant lymphomas: A multidisciplinary approach. The Kaplan Memorial Lec-ture. Ann Oncol (Suppl) 1994; 5 (2): 5–16. (P1/52)
   Google Scholar
• Blaney DW, Longo DL, Young RC, et al. Decreasing risk of leukemia with prolonged follow up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987; 316: 710-4. (R1/192)
   Google Scholar
• Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15: 528-34. (P2/115)
   Google Scholar
• Enblad G, Glimelius B, Hagberg H, et al. Methyl-GAG, Ifosfamide, Methotrexate and Etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphomas. Acta Oncol 1990; 29: 297-301. (P2/68)
   Google Scholar
• Longo DL, Duffey PL, Young RC, et al. Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 1992; 10: 210-8. (R1/107)
   Google Scholar
• Armitage JO. Early bone marrow transplantation in Hodgkin's disease. Ann Oncol (Suppl) 1994; 5 (2): 161–3. (R1/442)
   Google Scholar
• Ahmed T, Lake DE, Beer M, et al. Single and double autotransplants for relapsing/refractory Hodgkin's disease: Results of two consecutive trials. Bone Marrow Transplant 1997; 19: 449-54. (P1/122)
   Google Scholar
• Andersson PO, Brune M, Ekman T. Remission inversion and no transplant-related mortality - A single centre expe-rience of autologous stem cell transplantation in malignant lymphoma. Acta Oncol 2000; 39: 849–56.
   Google Scholar
• Burns LJ, Daniels KA, McGalve PB, et al. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: Factors predictive of prolonged survival. Bone Mar-row Transplant 1995; 16: 13-8. (R2/62)
   Google Scholar
• Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplanta-tion for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801-13. (R2/119)
   Google Scholar
• Josting A, Katay I, Rueffer U, et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell transplantation at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 1998; 9: 289-95. (P3/26)
   Google Scholar
• Josting A, Reiser M, Rueffer U, et al. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure? J Clin Oncol 2000; 18: 332–9. (P2/67, 25 transpl)
   Google Scholar
• Lancet JE, Rapoport AP, Brasacchio R, et al. Autotrans-plantation for relapsed or refractory Hodgkin's disease: Long-term follow up and analysis of prognostic factors. Bone Marrow Transplant 1998; 22: 264-71. (R3/70)
   Google Scholar
• O'Brien ME, Milan S, Cunningham D, et al. High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease-a pragmatic prognostic index. Br J Cancer 1996; 73: 1272-7. (R2/89)
   Google Scholar
• Reece DE, Barnett MJ, Shepherd JD, et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV + P) and au-tologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995; 86: 451-6. (P2/30)
   Google Scholar
• Ribrag V, Nasr F, Bouhris JH, et al. VIP (etoposide, ifos-famide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. Bone Marrow Transplant 1998; 21: 969-74. (P2/42)
   Google Scholar
• Lazarus HM, Rowlings PH, Zhang MJ, et al. Autotrans-plants for Hodgkin's disease in patients never achieving remission: A report from the autologous blood and marrow transplant registry. J Clin Oncol 1999; 17: 534-45. (R1/122)
   Google Scholar
• Sweetenham JW, Carella AM, Taghipour G, et al. High-dose therapy and autologous stemcell transplantation for adult patients with Hodgkin's disease who do not enter remisson after induction chemotherapy results in 175 patients re-ported to the European Group for Blood and Marrow Transplantation. J Clin Oncol 1999; 17: 3101-9. (R1/175)
   Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al. Dose intensifi-cation with autologous bone-marrow transplantation in re-lapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-4. (C2/40)
   Google Scholar
• Schmitz N, Sextro M, Pfistner B, et al. High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD). Final results of a randomised GHSG and EBMT trial (HD-R1). Proc Am Soc Clin Oncol, 1999; 18: 5 Abstr. (C3/142)
   Google Scholar
• André M, Henry-Amar M, Pico J-L, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study. J Clin Oncol 1999; 17: 222-9. (R3/86)
   Google Scholar
• Yuen AR, Rosenberg SA, Hoppe RT, et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's dis-ease. Blood 1997; 89: 814-22. (R3/60)
   Google Scholar
• Joly F, Henry-Amar M, Arveux P, et al. Late psychosocial sequelae in Hodgkin's disease survivors: A French popula-tion based case-control study. J Clin Oncol 1996; 14: 2444-53. (R1/93)
   Google Scholar
• Loge JH, Abrahamsen AF, Ekeberg O, et al. Psychological distress after cancer cure: a survey of 459 Hodgkin's disease survivors. Br J Cancer 1997; 76: 791-6. (R1/459)
   Google Scholar
• Abrahamsen AF, Loge JH, Hannisdal E, et al. Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution. Eur J Cancer 1998; 34: 1865-70. (R1/459)
   Google Scholar
• Loge JH, Abrahamsen AF, Ekeberg O, et al. Reduced health-related quality of life among Hodgkin's disease sur-vivors: A comparative study with general population norms. Ann Oncol 1999; 10: 71-7. (R1/459)
   Google Scholar
• Kornblith AB, Herndon II JE, Zuckerman E, et al. Compari-son of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Ann Oncol 1998; 9: 297-306. (R1/273)
   Google Scholar
• Johansson AS, Erlanson M, Lenner P, et al. Late side effects common after treatment for Hodgkin's disease; muscular atrophy following radiotherapy a neglected risk. Läkartid-ningen (Swedish) 1998; 95: 44-7. (R2/99)
   Google Scholar
• Abrahamsen AF, Loge JH, Hannisdal E, et al. Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease. Acta Oncol 1999; 38: 511-5. (R1/221)
   Google Scholar